Literature DB >> 26992378

Adhesion molecules and the extracellular matrix as drug targets for glioma.

Toshihiko Shimizu1, Kazuhiko Kurozumi2, Joji Ishida1, Tomotsugu Ichikawa1, Isao Date1.   

Abstract

The formation of tumor vasculature and cell invasion along white matter tracts have pivotal roles in the development and progression of glioma. A better understanding of the mechanisms of angiogenesis and invasion in glioma will aid the development of novel therapeutic strategies. The processes of angiogenesis and invasion cause the production of an array of adhesion molecules and extracellular matrix (ECM) components. This review focuses on the role of adhesion molecules and the ECM in malignant glioma. The results of clinical trials using drugs targeted against adhesion molecules and the ECM for glioma are also discussed.

Entities:  

Keywords:  Adhesion molecules; Angiogenesis; Extracellular matrix; Invasion; Malignant glioma

Mesh:

Substances:

Year:  2016        PMID: 26992378     DOI: 10.1007/s10014-016-0261-9

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  16 in total

1.  Molecular alterations in pediatric gliomatosis cerebri are similar to those in less invasive forms of pediatric diffuse glioma.

Authors:  Blandine Boisselier; Emilie De Carli; Audrey Rousseau
Journal:  J Neurooncol       Date:  2017-04-18       Impact factor: 4.130

2.  Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma.

Authors:  Mohan S Nandhu; Prajna Behera; Vivek Bhaskaran; Sharon L Longo; Lina M Barrera-Arenas; Sadhak Sengupta; Diego J Rodriguez-Gil; E Antonio Chiocca; Mariano S Viapiano
Journal:  Clin Cancer Res       Date:  2017-11-16       Impact factor: 12.531

Review 3.  Covalent nano delivery systems for selective imaging and treatment of brain tumors.

Authors:  Julia Y Ljubimova; Tao Sun; Leila Mashouf; Alexander V Ljubimov; Liron L Israel; Vladimir A Ljubimov; Vida Falahatian; Eggehard Holler
Journal:  Adv Drug Deliv Rev       Date:  2017-06-10       Impact factor: 15.470

4.  Molecular Subtypes and Prognostic Signature of Pyroptosis-Related lncRNAs in Glioma Patients.

Authors:  Guilong Tanzhu; Na Li; Zhanzhan Li; Rongrong Zhou; Liangfang Shen
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

Review 5.  Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review.

Authors:  Ahmed M Al-Abd; Abdulmohsin J Alamoudi; Ashraf B Abdel-Naim; Thikryat A Neamatallah; Osama M Ashour
Journal:  J Adv Res       Date:  2017-06-27       Impact factor: 10.479

6.  Promoter-Specific Expression and Genomic Structure of IgLON Family Genes in Mouse.

Authors:  Taavi Vanaveski; Katyayani Singh; Jane Narvik; Kattri-Liis Eskla; Tanel Visnapuu; Indrek Heinla; Mohan Jayaram; Jürgen Innos; Kersti Lilleväli; Mari-Anne Philips; Eero Vasar
Journal:  Front Neurosci       Date:  2017-02-02       Impact factor: 4.677

7.  High expression of GALNT7 promotes invasion and proliferation of glioma cells.

Authors:  Shi Hua; Hongyan Li; Yuguang Liu; Jian Zhang; Yanhao Cheng; Chao Dai
Journal:  Oncol Lett       Date:  2018-09-25       Impact factor: 2.967

Review 8.  Pro- and Antiangiogenic Factors in Gliomas: Implications for Novel Therapeutic Possibilities.

Authors:  Magdalena Groblewska; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

9.  COL3A1 and SNAP91: novel glioblastoma markers with diagnostic and prognostic value.

Authors:  Yuan-Feng Gao; Xiao-Yuan Mao; Tao Zhu; Chen-Xue Mao; Zhi-Xiong Liu; Zhi-Bin Wang; Ling Li; Xi Li; Ji-Ye Yin; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Oncotarget       Date:  2016-10-25

10.  Risk assessment model constructed by differentially expressed lncRNAs for the prognosis of glioma.

Authors:  Chenggong Hu; Yongfang Zhou; Chang Liu; Yan Kang
Journal:  Oncol Rep       Date:  2018-08-10       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.